Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Richard D CarvajalPaul D NathanJoseph J SaccoMarlana OrloffLeonel F Hernandez-AyaJessica YangJason John LukeMarcus O ButlerSarah StanhopeLaura CollinsCheryl McAlpineChris HollandShaad E AbdullahTakami SatoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Using a step-up dosing regimen of tebentafusp allowed a 36% increase in the RP2D compared with weekly fixed dosing, with a manageable side-effect profile and a signal of efficacy in mUM.
Keyphrases